← Back to Search

Nonsteroidal Anti-inflammatory Drug

Topical Diclofenac for Non-melanoma Skin Cancer

Phase 2
Waitlist Available
Led By Craig Elmets, MD
Research Sponsored by University of Alabama at Birmingham
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
ECOG performance status 0-1
Willing to abstain from chronic NSAID and COX-2 inhibitor use (other than cardioprotective doses of aspirin < 100 mg po QD) for the duration of the study. For routine analgesia, subjects may take acetaminophen as necessary.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Study Summary

This trial will study the effects of a topical medication, diclofenac, on the prevention of non-melanoma skin cancers. The study will also assess the optimal dose of the medication. Diclofenac is already approved by the FDA for other uses. 24 patients will be enrolled in the study.

Who is the study for?
This trial is for adults with good performance status, not undergoing other cancer treatments or major surgery within the last month. They must avoid certain medications and be willing to stop using topical products on damaged skin areas, except moisturizers and sunscreens. Women of childbearing age should use contraception and have a negative pregnancy test.Check my eligibility
What is being tested?
The study tests if diclofenac cream can prevent non-melanoma skin cancers by reversing biomarkers in the skin. It's a small-scale trial at University of Alabama involving 24 patients to find the best dose. Diclofenac is FDA-approved for other uses but not yet for this one.See study design
What are the potential side effects?
Potential side effects may include local skin reactions like redness, itching or rash where the cream is applied. Since diclofenac is an NSAID, it could also cause systemic effects such as stomach upset or rarely allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am fully active or can carry out light work.
Select...
I agree not to take certain pain relievers, except for low-dose aspirin, during the study.
Select...
My blood, liver, and kidney tests are within normal ranges.
Select...
I am using birth control and have a negative pregnancy test.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Optimal Dosing of topical diclofenac and topical DFMO for the reduction of actinic keratoses
Optimal Dosing of topical diclofenac and topical DFMO for the reduction of non melanoma skin cancer biomarkers

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: diclofenac once dailyActive Control1 Intervention
Topical diclofenac, will will be applied onto the skin of one arm, every day for 30 days. Enough medication will be used to cover an area of approximately 4 square inches( a 2 inch by 2 inch square). The medications will come in a tube. The medications will be applied to the same sun exposed site on the arm every day. The research team will provide instructions for the correct application of the treatment.
Group II: placeboPlacebo Group1 Intervention
The topical medication will will be applied onto the skin of one arm, once daily for 30 days. Enough placebo will be used to cover an area of approximately 4 square inches( a 2 inch by 2 inch square). The placebo will come in a tube. The placebo will be applied to the same sun exposed site on the arm every day. The research team will provide instructions for the correct application of the treatment.

Find a Location

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor
1,581 Previous Clinical Trials
2,278,005 Total Patients Enrolled
4 Trials studying Non-melanoma Skin Cancer
162 Patients Enrolled for Non-melanoma Skin Cancer
Craig Elmets, MDPrincipal InvestigatorUniversity of Alabama at Birmingham
2 Previous Clinical Trials
70 Total Patients Enrolled
1 Trials studying Non-melanoma Skin Cancer

Media Library

Diclofenac (Nonsteroidal Anti-inflammatory Drug) Clinical Trial Eligibility Overview. Trial Name: NCT02636569 — Phase 2
Non-melanoma Skin Cancer Research Study Groups: diclofenac once daily, placebo
Non-melanoma Skin Cancer Clinical Trial 2023: Diclofenac Highlights & Side Effects. Trial Name: NCT02636569 — Phase 2
Diclofenac (Nonsteroidal Anti-inflammatory Drug) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02636569 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To what ailments is diclofenac regularly prescribed?

"diclofenac is commonly used to treat catarrh and given once daily. It has also been used as an intervention for other conditions like photorefractive keratectomy, muscle strain, and osteoarthritis of the hands."

Answered by AI

Are there other examples of diclofenac being taken once every day during a clinical trial?

"There are a total of 19 clinical studies currently underway that are researching the effects of diclofenac administered once daily. Out of those 19 active trials, 5 have reached Phase 3. The majority of research locations for diclofenac are located in Beijing, but there are a total of 46 research sites spread out across the world."

Answered by AI

Is it dangerous to take diclofenac regularly?

"While diclofenac's efficacy is unproven, there is some evidence that suggests it is safe. Consequently, it received a score of 2."

Answered by AI
~3 spots leftby Apr 2025